Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials

Br J Clin Pharmacol. 2021 Mar;87(3):1584-1586. doi: 10.1111/bcp.14466. Epub 2020 Jul 14.

Emma H Baker^{1

2}, Kamal Patel³, Jonathan Ball⁴, Sarah Edwards⁵, Thomas S Harrison^{1

6}, Arvind Kaul⁷, Mickey Koh⁸, Sanjeev Krishna^{1

6

9

10}, Susannah Leaver⁴, Vinodh Kumar², Daniel M Forton^{1

3}

¹ Institute of Infection and Immunity, St George's, University of London, London, UK.
² Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK.
³ Department of Gastroenterology and Hepatology, St George's University Hospitals NHS Foundation Trust, London, UK.
⁴ Adult Critical Care Directorate, St George's University Hospitals NHS Foundation Trust, London, UK.
⁵ Department of Science and Technology Studies, University College London, London, UK.
⁶ Clinical Infection Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
⁷ Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK.
⁸ Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK.
⁹ Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany.
¹⁰ Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.

No abstract available

Publication types